<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">
  <channel>
    <title>HIV/AIDS Treatment News from POZ and AIDSmeds</title>
    <link>http://www.poz.com</link>
    <description><![CDATA[POZ, founded in 1994, and AIDSmeds, founded in 1999, are dedicated to providing people living with HIV/AIDS with the information they need to make empowered treatment decisions. ]]></description>
    <TTL>3</TTL>
    <generator>Smart &amp; Strong CMS 3.1.0</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <language>en</language>
    <pubDate>Fri, 6 Nov 2009 13:43:15 -0500</pubDate>
    <lastBuildDate>Fri, 6 Nov 2009 13:43:15 -0500</lastBuildDate>
    <item>
      <title>Rochester Researchers Explore Possible HIV-Associated Hearing Loss</title>
      <link>http://www.poz.com/rssredir/articles/hiv_hearing_loss_761_17526.shtml</link>
      <description><![CDATA[Specialists in HIV and in hearing at the University of Rochester Medical Center in New York State and are gearing up to conduct what they believe is the first large study to examine potential connections between HIV infection and hearing loss. The study, announced in a November 5 press release, is being supported by a $1.9 million grant from the National Institute on Deafness and Other Communication Disorders.]]></description>
      <pubDate>Fri, 6 Nov 2009 00:00:00 -0500</pubDate>
    </item>
    <item>
      <title>No Heart Rhythm Problem With 25 mg of Rilpivirine</title>
      <link>http://www.poz.com/rssredir/articles/hiv_rilpivirine_tmc278_761_17521.shtml</link>
      <description><![CDATA[People taking a 25 mg once-daily dose of rilpivirine (TMC278) had no signs of trouble with their heart rhythm, according to a study presented November 1 at the Infectious Disease Society of America conference in Philadelphia and reported by the National AIDS Treatment Advocacy Project (NATAP). These study results are encouraging, as this is the dose being explored for use in people starting HIV treatment for the first time.&nbsp;

]]></description>
      <pubDate>Thu, 5 Nov 2009 00:00:00 -0500</pubDate>
    </item>
    <item>
      <title>Many HIV-Positive Swiss MSM Have Chlamydia&amp;#8212;and Don&amp;#8217;t Know It</title>
      <link>http://www.poz.com/rssredir/articles/hiv_rectal_chlamydia_761_17514.shtml</link>
      <description><![CDATA[More than 10 percent of Swiss HIV-positive men who have sex with men (MSM) were infected with rectal <span style="font-style: italic;">Chlamydia trachomatis</span>&#8212;many without knowing it&#8212;according to a study published November 15 in <span style="font-style: italic;">Clinical Infectious Diseases</span> and reported by aidsmap.com.

]]></description>
      <pubDate>Wed, 4 Nov 2009 00:00:00 -0500</pubDate>
    </item>
    <item>
      <title>Coffee Lowers Risk of Hep C Progression</title>
      <link>http://www.poz.com/rssredir/articles/hiv_hcv_coffee_761_17506.shtml</link>
      <description><![CDATA[People with hepatitis C virus (HCV) who drank three or more cups of coffee per day had a 53 percent lower risk of liver disease progression than those who didn&#8217;t drink coffee, according to a study published in the November issue of <span style="font-style: italic;">Hepatology</span> and reported by ScienceDaily. The people in the study were infected only with HCV and not with both HIV and HCV.

]]></description>
      <pubDate>Mon, 2 Nov 2009 00:00:00 -0500</pubDate>
    </item>
  </channel>
</rss>
